DBV Technologies S.A. (DBVT)

Market Cap	269.13M
Revenue (ttm)	9.73M
Net Income (ttm)	-75.79M
Shares Out	199.36M
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,989
Open	1.38
Previous Close	1.38
Day's Range	1.33 - 1.40
52-Week Range	1.08 - 3.43
Beta	1.24
Analysts	Buy
Price Target	2.92 (+116.3%)
Earnings Date	Mar 2, 2023

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT

Financial Performance

In 2021, DBVT's revenue was 5.71 million, a decrease of -49.38% compared to the previous year's 11.28 million. Losses were -97.81 million, -38.70% less than in 2020.

Financial numbers in EUR

Analyst Forecast

According to 10 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is $2.92, which is an increase of 116.30% from the latest price.

Price Target

$2.92

(116.30% upside)

Analyst Consensus: Buy